UNICANCER: Adenocarcinoma trials

The registry lists 10 Adenocarcinoma studies with UNICANCER as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 7Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years OldNot yet recruitingNCT07118800Phase 3
• Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal AdenocarcinomaRecruitingNCT06846346Phase 2
• Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction CancerActive, not recruitingNCT05476796Phase 2
• Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcerCompletedNCT03777813Phase 2
• Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal AdenocarcinomasTerminatedNCT03722108Phase 1/2
• Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After ProstatectomyActive, not recruitingNCT01994239Phase 2
• A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of RelapseActive, not recruitingNCT01952223Phase 3
• Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following SurgeryCompletedNCT01780220Phase 1/2
• Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic AdenocarcinomaCompletedNCT01526135Phase 3
• MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal AdenocarcinomaCompletedNCT01443065Phase 2